万泰生物：九价HPV疫苗上市许可申请获受理

Investment Rating - The investment rating for the company is "Buy" [12]. Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2024, with revenue at 1.366 billion yuan, down 67.19% year-on-year, and net profit at 260 million yuan, down 84.70% year-on-year [2][6]. - The company is advancing its product pipeline, including the acceptance of the application for the nine-valent HPV vaccine, which is expected to enhance its market position [5][6]. - The company has achieved market access for its bivalent HPV vaccine in 18 countries and is actively pursuing further international market development [6]. Financial Performance Summary - For 2024, the company expects revenues of 2.715 billion yuan, a decrease of 50.74% year-on-year, with a projected net profit of 558 million yuan, down 55.31% year-on-year [7]. - The company’s earnings per share (EPS) for 2024 is estimated at 0.44 yuan, with a compound annual growth rate (CAGR) of 46.61% from 2024 to 2026 [7]. - The company’s financial metrics indicate a significant drop in profitability, with EBITDA projected to be 1.199 billion yuan in 2024, down from 1.556 billion yuan in 2023 [4][7]. Market Position and Product Development - The company is the first domestic supplier of HPV vaccines, which positions it favorably in the market [7]. - The nine-valent HPV vaccine has completed key clinical trials and is on track for commercialization, with priority review status granted by the National Medical Products Administration [6][7]. - The company is also developing a 20-valent pneumonia conjugate vaccine and a new freeze-dried varicella vaccine, indicating a robust pipeline of products [6].